Group 1
     (n = 53)

   Group 2
    (n = 39)

      p

Mean sC +/- SD   (Range 0.6- 1.2) (mg/dL)

BD
BL
18 months

 

1.36 +/- 0.8
1.64 +/- 1.1
4.1   +/- 1.4

 

1.27 +/- 0.9
1.6   +/- 1.22
1.31 +/- 1.1

 

ns
ns
< 0.05

Mean CCr +/- SD (Range 85- 140) (ml/min)

BD
BL
18 months

 

71.6 +/- 30.5
47.4 +/- 20.7
14.8 +/- 23

 

69.1 +/- 25
40.6 +/- 17.5
68.5 +/- 18.1

 

ns
ns
< 0.05

BKV load (x 10 ^ 4 cp/ml)

BL
3 months
6 months
9 months
12 months
18 months

 

14.2 +/- 7.5
11.8 +/- 5.6
8.52+/- 4.97
6.5  +/- 5.3
1.85 +/- 4.1
1.73 +/- 2.43

 

11.46 +/- 7.84
 3.06 +/- 2.83
 1.38 +/- 0.42
 1.14 +/- 0.49
 1.10 +/- 0.53
 1.00 +/- 0.53

 

ns
< 0.05
< 0.05
< 0.05
ns
ns

Mean time from RT to BL (months)

4.1 +/- 1.5

  4.7 +/- 1.8

ns

Mean time to clear BKV load (months)

9

3

<0.05

PVAN stage

*
A
B

 

2
2
1

 

2
1
1

 

AR treated FU

7

        --

 

Major graft functional decline (Graft loss)

19 (12)

5 (0)

 

Mean time to BKV urinary shedding (months)

3.9 +/- 1.7

4  +/- 2.1

ns

Mean time to clear BKV urinary load (months)

 13.6 +/- 8.3

 7.3 +/- 4.5

< 0.05
At the end of follow-up the mean graft function was declined in Group 1 affected recipients and it was stable in Group 2 affected recipients. The mean time for diagnosis of BKV-viremia was similar in two groups. At diagnosis of BKV-viremia the mean blood viral load was similar in two groups. In Group 2 the larger clearance of the mean blood viral load decreased significantly since the third month after therapeutic intervention. In Group 1 the larger clearance of the mean blood viral load decreased significantly since the ninth month after therapeutic intervention. 7 affected recipients of Group 1developed a new AR episode and 19 affected recipients had a major graft functional decline (12 had graft loss and 7 had doubling of serum creatinine) after therapeutic intervention. sC = serum creatinine, CCr = creatinine clearance, SD = standard deviation, BD = before diagnosis, BL = base line, FU = follow-up, RT = renal transplant, AR = acute rejection, cp = copies, * = presumptive PVAN. Lab value in International Units; reference range in International Units.
Table 3: BKV-related outcomes in two groups of recipients.